anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nanodiamonds (NDs) have garnered attention in the field of nanomedicine due to their unique properties. This review offers a comprehensive overview of NDs synthesis methods, properties, and their uses in biomedical applications. Various synthesis techniques, such as detonation, high-pressure, high-temperature, and chemical vapor deposition, offer distinct advantages in tailoring NDs' size, shape, and surface properties. Surface modification methods further enhance NDs' biocompatibility and enable the attachment of bioactive molecules, expanding their applicability in biological systems. NDs serve as promising nanocarriers for drug delivery, showcasing biocompatibility and the ability to encapsulate therapeutic agents for targeted delivery. Additionally, NDs demonstrate potential in cancer treatment through hyperthermic therapy and vaccine enhancement for improved immune responses. Functionalization of NDs facilitates their utilization in biosensors for sensitive biomolecule detection, aiding in precise diagnostics and rapid detection of infectious diseases. This review underscores the multifaceted role of NDs in advancing biomedical applications. By synthesizing NDs through various methods and modifying their surfaces, researchers can tailor their properties for specific biomedical needs. The ability of NDs to serve as efficient drug delivery vehicles holds promise for targeted therapy, while their applications in hyperthermic therapy and vaccine enhancement offer innovative approaches to cancer treatment and immunization. Furthermore, the integration of NDs into biosensors enhances diagnostic capabilities, enabling rapid and sensitive detection of biomolecules and infectious diseases. Overall, the diverse functionalities of NDs underscore their potential as valuable tools in nanomedicine, paving the way for advancements in healthcare and biotechnology.
Disclosed in the present invention is use of acylated spiramycin in medicaments for treating coronavirus diseases. In the present invention, computer simulation is used to prove that isovalerylspiramycin I, which is one of the main active ingredients of carrimycin, binds to a coronavirus S protein and a host cell receptor ACE2 protein thereof, and to show that isovalerylspiramycin I has potential ACE2 inhibitory activity. The expression of ACE2 will decrease after coronavirus infection, thereby increasing the lung damage. After isovalerylspiramycin I binds to ACE2, on the one hand, the function of ACE2 can be inhibited, and on the other hand, the stability of ACE2 can increase, and the decrease of the ACE2 expression after coronavirus infection can be inhibited. Isovalerylspiramycin I can also bind strongly to an inhibitory site of coronavirus main protease Mpro, thereby inhibiting the transcription and replication of coronavirus. Both in vitro and in vivo experiments show that carrimycin and the main active ingredients thereof can inhibit coronavirus and diseases caused by coronavirus.
OBJECTIVES: I. Determine the toxicity and activity of cyclophosphamide, etoposide, total body irradiation, and autologous bone marrow transplantation in patients with relapsed or refractory non-Hodgkin's lymphoma. II. Determine the feasibility of pretransplantation cytoreduction with a regimen of high-dose cytarabine, cisplatin, and dexamethasone in this patient population. III. Determine the feasibility of posttransplantation radiotherapy given to sites of residual disease (involved-field "boost" irradiation) in this patient population.

OUTLINE: Patients are stratified by disease status (refractory vs relapsed). Autologous bone marrow is harvested before cytoreduction or involved field radiotherapy (IFRT). Patients with marrow involvement who achieve marrow complete response after cytoreduction undergo harvest of bone marrow before IFRT. Patients receive cytoreduction comprising high-dose cytarabine IV over 1 hour every 12 hours, cisplatin IV over 10 hours, and dexamethasone three times daily on days 1 and 2. At 3 weeks, a second course is administered if tumor reduction is at least 25% and in the absence of unacceptable toxicity. Patients with involved sites 2 cm or greater in diameter at evaluation and previously unirradiated active disease sites, at least 90% of which can be treated with IFRT, undergo IFRT 5 days a week for 2 weeks beginning after cytoreduction and 3-5 weeks after harvest of bone marrow. Within 10 days after completion of IFRT, patients receive etoposide IV over 26 hours beginning on day -7, cyclophosphamide IV over 2 hours on days -6 to -4, and total body irradiation twice daily on days -3 and -2 and once on day -1. Bone marrow is reinfused on day 0. Eligible patients with residual disease at 3 months after transplantation undergo involved field "boost" irradiation to sites of residual disease.

PROJECTED ACCRUAL: Approximately 50 patients (25 per stratum) will be accrued for this study.
The invention provides a low-impurity levorotatory oxiracetam injection, which is characterized by comprising the following original auxiliary materials: levorotatory oxiracetam, glycerol, glycine, vitamin C, and ethylene diamine tetraacetic acid. The above materials are subjected to concentration proportion, dilution proportion, embedment, disinfection, examination, packaging and the like to prepare the levorotatory oxiracetam injection. The prepared levorotatory oxiracetam injection is not easily oxidized during the storage process, and the increased amount of impurities during the sterilization process is only 0.03%. Therefore, the levorotatory oxiracetam injection is good in stability and the validity period of the levorotatory oxiracetam injection is as long as 18 months. Within the validity period of the levorotatory oxiracetam injection, the levorotatory oxiracetam injection has fewer impurities and the total impurity content of the levorotatory oxiracetam injection is smaller than 0.26%. The obtained product is good in clarity and the clarity of the product is smaller than that of a No. 0.5 standard turbidity solution. The product is good in main drug solubility, and the sizes of insoluble particles in the product are smaller than 25 mum. The preparation process of the product is simple and feasible, thus being worthy of market promotion.
Aerosols suitable for inhalation by humans contain (a) prostaglandins (pref. prostaglandin E compounds) such as prostaglandins and/or analogues and derivs. thereof and/or cyclodextrin clathrates of these cpds and/or the non-toxic salts of the prostagladins and/or their analogues, and (b) a pharmaceutically acceptable liquid medium which is suitable for oral administration (pref. ethanol, aqueous ethanol or water), together with (c) a carbohydrate such as sucrose, fructose, maltose, glucose, xylose, mannose, xylitol and/or mannitol and, opt. (d) cinnamon oil or peppermint oil. Prostaglandins are useful in the treatment of hypertension, thrombosis, asthma and gastrointestinal ulcers, in the induction of labour, in the induction of abortion and for inhibiting arteriosclerosis.
Idiopathic granulomatous mastitis (IGM) is a noncancerous, chronic inflammatory disorder of breast with unknown causes, posing significant challenges to the quality of life due to its high refractoriness and local aggressiveness. The typical symptoms of this disease involve skin redness, a firm and tender breast mass and mastalgia; others may include swelling, fistula, abscess (often without fever), nipple retraction, and peau d'orange appearance. IGM often mimics breast abscesses or malignancies, particularly inflammatory breast cancer, and is characterized by absent standardized treatment options, inconsistent patient response and unknown mechanism. Definite diagnosis of this disease relies on core needle biopsy and histopathological examination. The prevailing etiological theory suggests that IGM is an autoimmune disease, as some patients respond well to steroid treatment. Additionally, the presence of concurrent erythema nodosum or other autoimmune conditions supports the autoimmune nature of the disease. Based on current knowledge, this review aims to elucidate the autoimmune-favored features of IGM and explore its potential etiologies. Furthermore, we discuss the immune-mediated pathogenesis of IGM using existing research and propose immunotherapeutic strategies for managing this condition.
Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
Renal fibrosis is distinguished by the abnormal deposition of extracellular matrix and progressive loss of nephron function, with a lack of effective treatment options in clinical practice. In this study, we discovered that the Beclin-1-derived peptide MP1 significantly inhibits the abnormal expression of fibrosis and epithelial-mesenchymal transition-related markers, including α-smooth muscle actin, fibronectin, collagen I, matrix metallopeptidase 2, Snail1, and vimentin both in vitro and in vivo. H&E staining was employed to evaluate renal function, while serum creatinine (Scr) and blood urea nitrogen (BUN) were used as main indices to assess pathologic changes in the obstructed kidney. The results demonstrated that daily treatment with MP1 during the 14-day experiment significantly alleviated renal dysfunction and changes in Scr and BUN in mice with unilateral ureteral obstruction. Mechanistic research revealed that MP1 was found to have a significant inhibitory effect on the expression of crucial components involved in both the Wnt/β-catenin and transforming growth factor (TGF)-β/Smad pathways, including β-catenin, C-Myc, cyclin D1, TGF-β1, and p-Smad/Smad. However, MP1 exhibited no significant impact on either the LC3II/LC3I ratio or P62 levels. These findings indicate that MP1 improves renal physiologic function and mitigates the fibrosis progression by inhibiting the Wnt/β-catenin pathway. Our study suggests that MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis. SIGNIFICANCE STATEMENT: This study indicated that the Beclin-1-derived peptide MP1 effectively mitigated renal fibrosis induced by unilateral ureteral obstruction through inhibiting the Wnt/β-catenin pathway and transforming growth factor-β/Smad pathway, thereby improving renal physiological function. Importantly, unlike other Beclin-1-derived peptides, MP1 exhibited no significant impact on autophagy in normal cells. MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis focusing on Beclin-1 derivatives and Wnt/β-catenin pathway.
PURPOSE: A composition containing bioconversion biomaterial of Angelica gigas Naka and Zizyphus jujuba var. inermis Rehder for suppressing angiogenesis is provided to suppress MMP(matrix metalloproteinase) activation, vascular endothelial cell migration and tube formulation. CONSTITUTION: An agent for anti-angiogenesis contains bioconversion biomaterials of Angelica gigas Naka and Zizyphus jujuba var. inermis Rehder produced by Aspergillus usamii var. shirousamii. A pharmaceutical composition for preventing and treating angiogenesis-relating diseases contains the bioconversion biomaterial. The daily dose of the composition is 0.1~100mg/kg once to three times a day. A method for producing the bioconversion biomaterial of the Angelica gigas Naka and Zizyphus jujuba var. inermis Rehder comprises: a step of culturing Aspergillus usamii var. shirousamii and collecting cells by centrifuging; a step of crushing the cells to obtain crude microorganism enzyme; a step of performing thermal extraction; a step of reacting the extract with crude enzyme liquid; and a step of sterilizing at 95°C for 30 minutes using 0.22 of filter.
INTRODUCTION: Inflammatory and immunological responses are reported involved in the pathogenesis and progression of obstructive nephropathy (ON). This study was designed to investigate the characteristics of peripheral immunity in patients with upper urinary tract urolithiasis and analyze the underlying associations with renal function.
METHODS: Patients with unilateral upper urinary tract urolithiasis meeting the operation indications were prospectively enrolled. Preoperative circulating immune cells and inflammatory cytokines were detected in our clinical laboratory, and the indicators of renal function and calculi related parameters were particularly recorded. Patients were sectionalized into subgroups on the basis of the lesion of calculi. Characteristics of peripheral immunity in each subgroup were investigated by statistical approaches, and the underlying correlations with the degree of hydronephrosis (HN) and renal function were discussed in corresponding group.
RESULTS: Patients with ureteral calculi presented severer HN compared with renal calculi, especial middle ureteral calculi, acting as the chief culprit of ON, exhibiting the highest serum creatine and blood urea nitrogen, most impaired estimated glomerular filtration rate, and severest HN. In addition, serum interleukin-8 (IL-8) and IL-6 were demonstrated presenting statistical differences between ureteral calculi and renal calculi patients, exhibiting underlying values in comprehending ON. However, circulating immune cells were demonstrated no obvious differences among groups.
CONCLUSIONS: Circulating inflammatory cytokines, referred in particular to serum IL-8 and IL-6 were partially associated with kidney injury in patients with upper urinary tract urolithiasis. But the specific influences and mechanisms between them needed to be investigated furthermore.
For the control group, we plan to use a mixture of 7.5 mL of 0.5% bupivacaine (BUVİCAİNE®) and 7.5 mL of 2% prilocaine (PRİLOC®) for a total of 15 mL. single shot supraclavicular brachial plexus block.
Patients with estrogen receptor (ER) positive metastatic breast cancer (MBC) starting their first line of endocrine therapy (ET) only have a 30-50% chance of receiving clinical benefit. For the other 50-70% of patients, ET is ineffective and these patients should probably be treated with chemotherapy, as is done for ER negative patients. More importantly, in nearly every clinical trial of ET in ER positive, MBC patients, between 15-30% of enrolled patients progress in the first 2-3 months, regardless of whether they are receiving first or later lines of ET. Currently there is no validated method to identify which ER positive MBC patients will be refractory to ET. Therefore, almost all ER positive patients are treated with serial endocrine therapies before switching to chemotherapy. The investigators propose that a subset of these patients would be better served with chemotherapy, in spite of its increased toxicity profile, rather than delaying chemotherapy during a several month trial of ineffective, albeit less toxic, ET.

To try and predict benefit from or resistance to ET, an index (the CTC-ETI) has been created that takes into account the number of CTC (which is prognostic) as well as the phenotype of the CTC, based on the hypothesis that relative levels of ER and Bcl-2 (high=benefit) and HER2 and Ki67 (high=resistance) are predictive of ET responsiveness or resistance. Although the preliminary data demonstrate the ability to detect, enumerate, and characterize CTC utilizing the CellSearch® System, the purpose of the current study is to establish proof of principle that these 4 markers can be used to generate a CTC-ETI which can be performed at baseline from patients enrolled at different centers, and that baseline CTC-ETI predicts relative outcome for patients with ER positive MBC starting a new ET, and can be monitored in such patients during ET. Successful completion of this study will set the stage for a larger, definitive study designed to demonstrate the clinical utility of a "refined" CTC-ETI in patients with ER positive, HER2 negative MBC.
<P>PROBLEM TO BE SOLVED: To provide new complexes of major histocompatibility complex (MHC) molecules, and to provide uses of such complexes.  <P>SOLUTION: Provided are single chain MHC class II complexes that include a class II β2 chain modification, e.g. deletion of essentially the entire class II β2 chain. In another aspect, provided is single chain MHC class II which comprises an immunoglobin constant chain or fragment. Further, provided are polyspecific MHC complexes comprising at least one single chain MHC class II molecule. The MHC complexes are useful for a variety of applications including: (1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and (2) methods for suppressing or inducing an immune response in a mammal.  <P>COPYRIGHT: (C)2009,JPO&INPIT
FIELD: veterinary science, immunology. SUBSTANCE: invention relates to the strain of hybrid cultured cells that produces monoclonal antibodies to the strain T-75. Monoclonal antibodies are referred to isotype IgG and show high reactivity in immunoenzyme analysis and neutralization reaction with homologous virus. Antibodies are detected in ascitic fluid in immunoenzyme analysis for 6-10 passages in mice (observation period) at dilution 10 -3 10 -5 .. Monoclonal antibodies can be used in veterinary practice for diagnosis and prophylaxis of diseases in agriculture animals. Obtained strain shows high productivity of monoclonal antibodies to the strain T-75. EFFECT: strain indicated above, increased production of antibodies. 1 tbl
A process for preparing an adhesive material for tooth fillings, consists in mixing a base of calcium hydroxide with up to 50 per cent by weight of dry casein powder.  The calcium hydroxide may be made from calcium oxide to which a watery solution containing sodium chloride, potassium chloride, calcium chloride and magnesium chloride is added.  The mixture of calcium hydroxide and these chlorides is then dried and casein powder added so that the finished dry mixture contains .522 per cent by weight of sodium chloride, .012 per cent by weight of potassium chloride, .012 per cent by weight of calcium chloride, .007 per cent by weight of magnesium chloride.  The dry mixture is stored in hermetically sealed flasks.  For application to a tooth some dry mixture is stirred with water to form a paste.  Some of the calcium hydroxide may be replaced by an equimolar amount of calcium oxide which is added to the dry mixture, the heat produced when water is added to the mixture before application assisting the stirring process.
The invention discloses a traditional Chinese medicine composition for treating eczema, a preparation method and a preparation thereof, and belongs to the technical field of traditional Chinese medicines. The composition combines various traditional Chinese medicines with effects of clearing heat, detoxicating, eliminating dampness and relieving itching, and is applied to affected parts, and has good curative effect and short treatment course. The common cnidium fruit and the gentian are used together to play a role in eliminating dampness and relieving itching, and have good curative effect on eczematous dermatitis. The combination of corydalis tuber and ground beetle has the wonderful idea of treating blood first and blood flowing wind self-extinguishing, and originally creates the idea of treating the exterior of the muscle from the blood system. Folium mori is bitter and cold in nature, has the effects of dispelling wind, clearing heat, clearing lung and moistening dryness, and is a new method for treating skin and hair from the lung and treating eczema by clearing lung heat. The composition completely adopts pure traditional Chinese medicinal materials, does not contain any hormone component, has no side effect, can only aim at single type of eczema compared with the traditional hormone ointment, can be used for various types of eczema, and has wide coverage and strong applicability.
FIELD: medicine, neurology, sports medicine, orthopedics. SUBSTANCE: preliminary electropuncture diagnostics and medicinal testing are conducted in patients to indicate homeopathic products along with those possessing spasmolytic, antiphlogistic, anesthetic and metabolic actions which are introduced perorally into a body 3-5 days before the onset of curative impact, during the whole course of therapy and 3-5 days after its finishing by combining with daily intake of distilled water on the empty stomach. Curative impact should be started with a massage of cervico-accipital region directed to reveal injured mobile segments of backbone and functional blocks followed by conducting point massage for biologically active points in combination with color-impulse therapy. Then at doing exercises of curative gymnastics after isometric muscular tension at inhalation their postisometric relaxation is conducted at expiration, manual therapy is carried out immediately after exercises complex. Curative seance is completed by electroneuroadaptive stimulation upon segments C 7 -C 1 . There are 3-10 seances per the whole therapy course. EFFECT: higher efficiency of therapy in patients of any age with no contraindications and complications due to individual approach and gradual preparing a patient to receive manual therapy. 7 cl
Since initially reported in Wuhan, China, in late December 2019, the outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has spread globally, stressing many health systems especially intensive care unit (ICU) capacities thus resulting in high mortality. On 16 March 2020, WHO Director-General called on all countries to ramp up their testing programs as the best way to slow the advance of the coronavirus pandemic. Although the current gold standard for COVID-19 diagnosis remains real time reverse transcription-polymerase chain reaction (rRT-PCR), this technique has many shortcomings such as low sensitivity on nasopharyngeal swabs (70%). Multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices. Before these tests can be recommended, they must be validated in the appropriate populations and settings.

Funded by French Defense Innovation Agency (AID), ERap-CoV is a prospective clinical study which aims to assess clinical performances of serological and antigenic assays for the diagnosis of SARS-CoV-2 infection, in comparison with current diagnostic tests on the market (immunological, proteomic, molecular). The ERap-CoV research will extend the clinical validation of the first NG-Test IgM-IgG COVID-19 point-of-care immunodiagnostic test (NG Biotech), which has shown excellent biological performance, compatible with the recommendations of the Haute Autorité de Santé (HAS) for serological assays (sensitivity\> 90% and specificity\> 98%, 15 days after symptoms) (1). Finally, AID funding will be used to develop 100% French-made serological and antigenic RDTs in less than a year.